This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Agani, F. Articles by Semenza, G. L. Search for Related Content PubMed PubMed Citation Articles by Agani, F. Articles by Semenza, G. L.

p53 Does Not Repress Hypoxia-induced Transcription of the Vascular Endothelial Growth Factor Gene¹

Departments of Pediatrics and Medicine and Center for Medical Genetics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 [F. A., G. L. S.]; Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 [D. G. K., M. B. K.]; and UCSF Liver Center Laboratory, San Francisco, California 94110 [S. L. F.]

Hypoxia-induced neovascularization mediated by vascular endothelial growth factor (VEGF) contributes to tumor progression. Based on its effects when overexpressed in transient transfection assays, p53 has been proposed to repress VEGF transcription. To investigate this hypothesis, we have analyzed endogenous VEGF mRNA levels in Hep3B cells stably expressing an inducible p53-estrogen receptor fusion protein and in irradiated RKO cells expressing endogenous wild-type p53. In both cell lines, VEGF mRNA levels increased in response to hypoxia, either in the presence or absence of functional p53. Our data provide no evidence for a causal relationship between the loss of p53 activity and increased VEGF expression that is observed during tumor progression. Studies that attribute repressor functions to p53 based on analysis of cells transiently overexpressing this protein should be interpreted cautiously.

¹ Supported in part by a Fulbright Senior Scholar Award (to S. L. F.), by grants from the American Heart Association National Center (to G. L. S.), and by NIH Grants R01-DK39869 and R01-HL55338 (to G. L. S.), R01-ES05777 and R01-CA61949 (to M. B. K.), T32-GM07309 (to D. G. K.), and R01-DK37340 (to S. L. F.). G. L. S. is an Established Investigator of the American Heart Association, and M. B. K. is the Steven Birnbaum Scholar of the Leukemia Society of America.

² To whom requests for reprints should be addressed, at Johns Hopkins Hospital, CMSC-1004, 600 North Wolfe Street, Baltimore, MD 21287-3914. Phone: (410) 955-1619; Fax: (410) 955-0484; E-mail: gsemenza@gwgatel.jhmi.jhu.edu.

Received 7/14/97. Accepted 8/29/97.

This article has been cited by other articles:

				Y. Sumiyoshi, Y. Kakeji, A. Egashira, K. Mizokami, H. Orita, and Y. Maehara Overexpression of Hypoxia-Inducible Factor 1{alpha} and p53 Is a Marker for an Unfavorable Prognosis in Gastric Cancer Clin. Cancer Res., September 1, 2006; 12(17): 5112 - 5117. [Abstract] [Full Text] [PDF]

				M. Kaluzova, S. Kaluz, M. I. Lerman, and E. J. Stanbridge DNA Damage Is a Prerequisite for p53-Mediated Proteasomal Degradation of HIF-1{alpha} in Hypoxic Cells and Downregulation of the Hypoxia Marker Carbonic Anhydrase IX Mol. Cell. Biol., July 1, 2004; 24(13): 5757 - 5766. [Abstract] [Full Text] [PDF]

				G. Hopfl, O. Ogunshola, and M. Gassmann HIFs and tumors--causes and consequences Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2004; 286(4): R608 - R623. [Abstract] [Full Text] [PDF]

				N. S Cherniack Oxygen sensing: applications in humans J Appl Physiol, January 1, 2004; 96(1): 352 - 358. [Abstract] [Full Text] [PDF]

				A. Yuan, C.-J. Yu, K.-T. Luh, S.-H. Kuo, Y.-C. Lee, and P.-C. Yang Aberrant p53 Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non-Small-Cell Lung Cancer J. Clin. Oncol., February 15, 2002; 20(4): 900 - 910. [Abstract] [Full Text] [PDF]

				S. Pal, K. Datta, and D. Mukhopadhyay Central Role of p53 on Regulation of Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Expression in Mammary Carcinoma Cancer Res., September 1, 2001; 61(18): 6952 - 6957. [Abstract] [Full Text] [PDF]

				L. Zhang, D. Yu, M. Hu, S. Xiong, A. Lang, L. M. Ellis, and R. E. Pollock Wild-Type p53 Suppresses Angiogenesis in Human Leiomyosarcoma and Synovial Sarcoma by Transcriptional Suppression of Vascular Endothelial Growth Factor Expression Cancer Res., July 1, 2000; 60(13): 3655 - 3661. [Abstract] [Full Text]

				K. R. Laderoute, R. M. Alarcon, M. D. Brody, J. M. Calaoagan, E. Y. Chen, A. M. Knapp, Z. Yun, N. C. Denko, and A. J. Giaccia Opposing Effects of Hypoxia on Expression of the Angiogenic Inhibitor Thrombospondin 1 and the Angiogenic Inducer Vascular Endothelial Growth Factor Clin. Cancer Res., July 1, 2000; 6(7): 2941 - 2950. [Abstract] [Full Text]

				G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak Vascular endothelial growth factor (VEGF) and its receptors FASEB J, January 1, 1999; 13(1): 9 - 22. [Abstract] [Full Text]

				G. Fontanini, L. Boldrini, A. Calcinai, S. Chine, M. Lucchi, A. Mussi, C. A. Angeletti, F. Basolo, and G. Bevilacqua Thrombospondins I and II Messenger RNA Expression in Lung Carcinoma: Relationship with p53 Alterations, Angiogenic Growth Factors, and Vascular Density Clin. Cancer Res., January 1, 1999; 5(1): 155 - 161. [Abstract] [Full Text] [PDF]

				M. Narimatsu, Y. Nagayama, K. Akino, M. Yasuda, T. Yamamoto, T.-t. Yang, A. Ohtsuru, H. Namba, S. Yamashita, H. Ayabe, et al. Therapeutic Usefulness of Wild-Type p53 Gene Introduction in a p53-Null Anaplastic Thyroid Carcinoma Cell Line J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3668 - 3672. [Abstract] [Full Text]